RESEARCH TRIANGLE PARK, N.C., Feb. 4, 2011 /PRNewswire/ —
Stiefel, a GSK company, today announced the launch of the
most-prescribed BPO Acne Wash formulations for over-the-counter
(OTC) use in the United States. The launch will occur in the
technical exhibit at the American Academy of Dermatology annual
meeting in New Orleans. Indicated for the treatment of acne,
Stiefel will market two products OTC under the PanOxyl®
Brand. PanOxyl® Acne Creamy Wash will be available
in 4% BPO and 8% BPO.
PanOxyl® 4% and 8% BPO Acne Creamy Washes feature a
patented delivery system including Dimethyl Isosorbide (DMI) that
solubilizes BPO and greatly reduces particulate-based skin
irritation and inflammation commonly experienced with conventional
BPO formulations. Both products are thick, creamy
formulations which provide excellent efficacy and rapid reduction
in acne lesions.
“Stiefel’s Creamy Wash formulations have been physician
favorites for several years,” said Shayne Sundholm, vice president,
U.S. Non Prescription Dermatology, Stiefel. “And we are
excited to be able to offer them to a larger number of consumers
through the retail market.”
A comprehensive marketing campaign directed toward
dermatologists and pharmacists will communicate details of the new
PanOxyl® 4% and 8% BPO Acne Creamy Washes. Product
will be available for shipment in May 2011.
PanOxyl® Acne Management product line offers different
formulations for the treatment and prevention of acne on the face,
chest and back.
About Stiefel, a GSK company
Stiefel, a GSK company, is committed to advancing dermatology
and skin science around the world in order to help people better
achieve healthier skin. Stiefel’s dedication to innovation,
along with its focus on pharmac
‘/>”/>
